Proactive Investors - Run By Investors For Investors

Genus on track to meet H2 targets as trading remains strong

Genus on track to meet H2 targets as trading remains strong

Animal genetics company Genus (LON:GNS) said that trading in the final two months of the financial year had been in line with expectations and it was on track to achieve an improvement in performance in the second half of the year.

Genus added that it had benefited from exchange rate movements and would report a small non-cash exceptional gain resulting from the closure to future accrual of defined benefit pensions in the Milk Pension Fund.

In a trading statement released in May, Genus reported an increased demand from customers in the North American market, which were looking to update the genetics in their herds as confidence in the strength of the recovery improved. Demand had also been strong in Latin America and China, while trading in Europe was in line with expectations.

View full GNS profile View Profile

Genus Timeline

February 16 2015

Related Articles

copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
tablets and pills
Here we take a closer look at Clinigen, the specialty pharma group and AIM billionaire
researcher at microscope
May 24 2019
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use